Press releases | WebDisclosure

Basculer en Français

9560	Companies
188851	Keywords
120589	Articles
100789	Press releases

Home
Press releases

PRESS RELEASE

published on 07/24/2025 at 08:00, 4 months 28 days ago

Transaction in Own Shares
Molten Ventures plc (GROW) announces transaction in own shares, with 50,000 ordinary shares purchased on 23 July 2025. Highest price: 348.60p, Lowest price: 343.00p

Share Repurchase Ordinary Shares Molten Ventures Plc Own Shares Transaction
PRESS RELEASE

published on 07/24/2025 at 08:00, 4 months 28 days ago

LPKF increases revenue in the first half of 2025 despite global uncertainties
LPKF reports 7.2% revenue growth in H1 2025 despite global uncertainties. Cost optimization boosts earnings. Order intake impacted by customers' investment reluctance

Revenue Growth Cost Optimization LPKF Global Uncertainties H1 2025
PRESS RELEASE

published on 07/24/2025 at 08:00, 4 months 28 days ago

vVARDIS’ Drill-Free Solution Curodont™ Has Treated Over One Million Teeth in 18 Months and Is the Fastest Growing Dental Care Product in Its Category
vVARDIS' Curodont™ drill-free solution has treated over one million teeth in 18 months, elevating caries management standards. Clinical experts praise it as a revolutionary advancement in dentistry

Innovation Dental Care VVARDIS Curodont™ Caries Management
PRESS RELEASE

published on 07/24/2025 at 08:00, 4 months 28 days ago

TRILOGIQ - Comptes consolidés annuels au 31 mars 2025
Trilogiq publie ses comptes consolidés annuels au 31 mars 2025, avec un chiffre d'affaires de 23.203 K€ et un excédent brut d'exploitation de 1.223 K€, marqués par une légère baisse et une optimisation des coûts

Chiffre D'affaires Baisse Comptes Consolidés Excédent Brut D'Exploitation TRILOGIQ
PRESS RELEASE

published on 07/24/2025 at 07:56, 4 months 28 days ago

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science receives approval from European countries to initiate Phase 3 study of masitinib in ALS following protocol validation by EMA and FDA

Phase 3 Study ALS AB Science Masitinib EMA
PRESS RELEASE

published on 07/24/2025 at 07:56, 4 months 28 days ago

AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l'étude confirmatoire de phase 3 avec le masitinib dans la sclérose latérale amyotrophique. Protocole validé par l'EMA et autorisation de la FDA

AB Science Masitinib Sclérose Latérale Amyotrophique Étude Confirmatoire Autorisation Européenne
PRESS RELEASE

published on 07/24/2025 at 07:37, 4 months 28 days ago

Résultats du premier semestre 2025
PRESS RELEASE

published on 07/24/2025 at 07:30, 4 months 28 days ago

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Suspension Temporaire
PRESS RELEASE

published on 07/24/2025 at 07:30, 4 months 28 days ago

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris. La suspension intervient dans le cadre de l'Offre d'American Depositary Shares

Euronext Paris Biotechnologie Abivax Offre Publique Suspension Temporaire
PRESS RELEASE

published on 07/24/2025 at 07:30, 4 months 28 days ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris due to public offering preparations

Euronext Paris Abivax Trading Halt Public Offering Clinical-stage Biotechnology

Accesswire

Published on 12/20/2025 at 00:30, 1 day 18 hours ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 1 day 20 hours ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 2 days ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 2 days 4 hours ago

Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 2 days 5 hours ago

Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE

EQS Group

Published on 12/21/2025 at 08:55, 10 hours 4 minutes ago

Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro
Published on 12/20/2025 at 16:45, 1 day 2 hours ago

Shanghai Electric Powers Up Iraq's Energy Future with Major 625MW Efficiency Upgrade
Published on 12/20/2025 at 10:05, 1 day 8 hours ago

FITUR 2026 highlights the strong synergies between Germany and Spain
Published on 12/19/2025 at 22:03, 1 day 20 hours ago

EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector
Published on 12/19/2025 at 21:40, 1 day 21 hours ago

IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries

Les Echos

Published on 12/19/2025 at 21:57, 1 day 21 hours ago

Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 2 days 10 hours ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 2 days 10 hours ago

Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 2 days 11 hours ago

EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 2 days 11 hours ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE